Department of Gynaecological Oncology, Chittaranjan National Cancer Institute, 37 S P Mukherjee Road, Kolkata-700026, West Bengal, India.
Department of Gynaecology and Obstetrics, Vivekananda Institution of Medical Sciences, 99 Sarat Bose Road, Kolkata-26, India.
Asian Pac J Cancer Prev. 2021 Mar 1;22(3):699-704. doi: 10.31557/APJCP.2021.22.3.699.
Initial introduction of HPV vaccination from 2006 to 2008 was largely confined to high-income countries (HIC), such as Australia, the United States, and Europe, where cervical cancer incidence is lowest. Much of the post-introduction literature has come from HICs, with a focus on coverage levels achieved, provider acceptability and early impact of vaccination on disease endpoints. However, there are a few literature evaluating the mechanics of delivery, feasibility of the health system and acceptability from low and middle income countries (LMICs). The primary objective was to evaluate the feasibility, acceptability and safety of two dose HPV vaccination in adolescent girls between 9-14 years.
After an orientation camp followed by filling up of prevaccine questionnaires by parents on HPV related diseases and its vaccines and informed consent, girls between9-14years were vaccinated. They were asked to report any side effects in the next 24 hours after each dose. Parents were contacted on Day 7 and Day 30 to enquire about any side effects . Total 3 visits were required i.e two for the vaccination and one visit at 7th month post completion of second dose. To estimate the acceptability, successful completion of two doses by at least 80% of the girls were measured. For measurement of acceptability, either of the parents were recalled along with their daughter at 7th month and were asked to fill up a pre-set questionnaire.
After institutional ethical clearance, 555 girls were recruited in the study from rural parts of West Bengal, India between July, 2017 to November, 2017. Out of which, 544 girls (98%) received their 2nd dose between January, 2018 and May, 2018 without any serious adverse effects. No serious adverse effect was reported on follow up till December, 2019.
The introduction of HPV vaccination is feasible in large scale and the vaccine is well accepted and safe.
.
HPV 疫苗于 2006 年至 2008 年首次引入，主要局限于澳大利亚、美国和欧洲等高收入国家（HIC），这些国家的宫颈癌发病率最低。大多数疫苗接种后文献来自 HIC，重点关注已实现的覆盖率、提供者的可接受性以及疫苗接种对疾病终点的早期影响。然而，只有少数文献评估了中低收入国家（LMIC）的疫苗接种提供机制、卫生系统的可行性和可接受性。主要目的是评估两剂 HPV 疫苗在 9-14 岁少女中的接种可行性、可接受性和安全性。
在参加了一个定向训练营并由父母填写了 HPV 相关疾病及其疫苗的预疫苗问卷和知情同意书后，为 9-14 岁的女孩接种疫苗。要求她们在每次接种后 24 小时内报告任何副作用。在第 7 天和第 30 天联系家长询问任何副作用。总共需要 3 次就诊，即两次接种和第二次接种完成后第 7 个月的一次就诊。为了评估可接受性，通过至少 80%的女孩完成两剂来衡量。为了测量可接受性，在第 7 个月，召回了至少一位父母及其女儿，并要求他们填写一份预先设定的问卷。
在获得机构伦理批准后，2017 年 7 月至 2017 年 11 月期间，在印度西孟加拉邦农村地区招募了 555 名女孩参加研究。其中，544 名女孩（98%）在 2018 年 1 月至 2018 年 5 月期间接受了第二剂疫苗，没有任何严重的不良反应。在 2019 年 12 月之前的随访中没有报告任何严重不良反应。
HPV 疫苗的引入是可行的，且疫苗接种规模大、接受度高、安全性好。
